Mesoblast [ASX:MSB] Shares Soar 10.5% for Remestemcel-L Progress
Mesoblast shares soared 10.5% for a list of updates pertaining to the company’s Remestemcel-L, including a biologic licence application and new data for the product’s effectiveness in improving inflammatory biomarkers and survival.





